论文部分内容阅读
目的:探讨不同阶段CEA水平变化评价非小细胞肺癌(non-small cell lung cancer,NSCLC)影像学DC的效能,寻找进一步提高CEA水平变化评价疗效的模式。方法:利用受试者工作特征曲线(receiver oper-ating characteristics curve,ROC)来回顾性研究53例晚期NSCLC患者不同阶段CEA变化单独和联合评价影像学DC的效能。结果:CEA1变化率和CEA2变化率评价DC的ROC面积分别为0.844和0.794(均P<0.01),阈值分别为-16.3%和-35.6%,此时敏感度和特异度均≥80.0%;CEA1变化和CEA2变化联合评价DC和单一指标评价疗效效能差别无统计学意义(P>0.05)。单因素分析和spearman相关分析均进一步证实了CEA1变化和CEA2变化在评价DC中的作用(均P<0.01)。结论:在CEA水平升高的晚期NSCLC患者中,CEA1变化率、CEA2变化率均可以有效评价化疗疗效,联合评价不能进一步提高评价效能。
Objective: To investigate the efficacy of different stages of CEA level changes in evaluating the efficacy of DC in non-small cell lung cancer (NSCLC) imaging and to find out the mode of further improving the efficacy of CEA. METHODS: The receiver operating characteristic (ROC) curve of receiver operating characteristic (ROC) was used to retrospectively study the efficacy of CEA in different stages of 53 patients with advanced NSCLC. Results: The ROC of DC with CEA1 rate of change and CEA2 rate of change were 0.844 and 0.794 (all P <0.01), the threshold values were -16.3% and -35.6%, respectively. The sensitivity and specificity were all ≥80.0% There was no significant difference in the curative effect between the change of CEA2 and the combined evaluation of DC and single index (P> 0.05). Univariate analysis and spearman correlation analysis further confirmed the role of CEA1 changes and CEA2 changes in the evaluation of DC (all P <0.01). CONCLUSION: CEA1 and CEA2 rates in advanced NSCLC patients with advanced CEA can effectively evaluate the efficacy of chemotherapy, and the combined evaluation can not further improve the evaluation efficacy.